So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
Chemicals are a critical, but often overlooked, factor of success for a circular economy. 96% of all products on European markets, from food to medical treatments, from buildings to consumer electronics, rely on chemicals, so this shouldn’t come as a surprise. But what does circularity mean for the future of the chemicals industry? Should it embrace circular systems or resist them?
Andreas Helget, Managing Director of Yokogawa Germany, about the importance of digital transformation on the way to autonomous systems.
In January, Schrödinger, a provider of integrated software solutions, and the life sciences company Bayer announced a 5-year technology alliance to develop a comprehensive de novo design solution to accelerate the discovery of innovative, high-quality drugs.
Innovative strength has been a cornerstone of Bachem’s business success since the founding nearly 50 years ago. Günther Loidl, Chief Technology Officer for Bachem Holding, talks about a new innovation management system that will further heighten the importance of innovation in the future.
So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.
DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.
The pharmaceutical industry is increasingly focused on the development of specialized drug products with new treatment modalities, including previously undruggable targets for oncology and other areas.
China`s 14th Five-Year Plan (FYP) covering the period from 2021 to 2025 will only be published after its acceptance by the National People`s Congress in March 2021.
Online Monitoring and Control of Bioreactors by Mid-Infrared Spectroscopy
Single-step, Ambient, Dry Grafting of Organic Compounds and Biomolecules onto any Substrate.
We are in the midst of a start-up revolution. The growth of innovation-driven start-up activity is profound and global in scope, and it is a driving force of change even in mature industries such as the chemical and pharmaceutical sector.
As a production and innovation partner, JRS Contract Manufacturing supports those involved in special projects in product development, series start-ups, implementation of marketing-relevant product features, process optimization or capacity expansion.
For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.
Andrew Badrot, CEO of C2 Pharma and a close observer of pharma industry trends, analyzes the current situation and how this pandemic may kick of changes in the pharma market.
Linde intends to further expand its hydrogen business by investing in electrolysis capacities and infrastructure.
The pressure to reduce costs and to improve production efficiency is increasing during the corona crisis. Digitalization offers corresponding levers here, but the mid-sized process industry in particular is not yet able to implement them profitably.
Synthace’s multidisciplinary team of researchers and software engineers have developed the Antha software platform to lower the barriers for scientists to execute sophisticated experiments with automated laboratory equipment.
Designed for their performance and durability, synthetic plastics have become indispensable as “materials of every-day use”. However, their characteristic long life span and indiscriminate disposal have led to an acute problem of plastic pollution. In order to address this issue, the European Union is not only trying to adopt a circular system to reuse, repair and recycle plastics (circular economy) but it also aims to produce plastics out of renewable resources (biobased plastics).
The WeylChem Group of companies consists of seven operating and two R&D sites in Europe and the USA as well as the global sales and marketing platform, WeylChem International.
The chemical industry is on the threshold of a new era – the age of circularity. We asked industry experts to share their opinions on this transformational topic.
Hybrid assemblies, joints of dissimilar materials, are everywhere - in our smartphones, cars, TVs, dishwashers, in planes and so on. However, in modern products we increasingly rely on plastics, which are intrinsically hard to bond to other types of material — and by using industrial glue for the bonding the parts cannot be recycled easily. Solving this monumental challenge inspired the foundation of the Danish start-up company RadiSurf five years ago.
Cellugy was founded two years ago by a diverse team of young academics and professionals from Spain, Indonesia, Albania, and Denmark. Working together at Aarhus University in Denmark, the idea of developing a material based on nanocellulose as an alternative to plastic barrier coatings arose and grew into a start-up and a first product. Co-founders Isabel Alvarez-Martos and Deby Fapyane talk about their motivation and vision.
Molecule.one leverages artificial intelligence (AI) to design novel chemical syntheses. As a response to the outbreak of the Covid-19 pandemic, the Polish start-up based in Warsaw has set out on the mission to accelerate the process of creating medicines.
Virtual Prototyping of Complex Fluids and Flowing Materials
Change is happening this very minute in the logistics industry. Why? Quite simply, because shippers are under enormous pressure from their customers to provide accurate real-time visibility data on shipments from pick-up to delivery.
As an independent system of uniform third party assessments, SQAS — Safety and Quality Assessment System —was initiated to evaluate the performance of logistics service providers and chemical distributors.
